Displaying 73 - 84 of 120
Cirrhosis & Complications
How do patients benefit from Albumin?

How do patients benefit from Albumin?

Webcasts
View
Cirrhosis & Complications
Summary and Conclusions “from a fluid to a  medicine”

Summary and Conclusions “from a fluid to a  medicine”

Webcasts
View
Cirrhosis & Complications
The effective albumin concentration: from hypothesis to reality

The effective albumin concentration: from hypothesis to reality

Webcasts
View
Cirrhosis & Complications
Welcome and Introduction

Welcome and Introduction

Webcasts
View
Cirrhosis & Complications
When Platelet Count Matters: Prophylaxis Ahead of Procedures in Chronic Liver Disease Patients (CLD)

When Platelet Count Matters: Prophylaxis Ahead of Procedures in Chronic Liver Disease Patients (CLD)

Webcasts
View
Metabolism, Alcohol & Toxicity
NASH: An evolution in treatment response tools

NASH: An evolution in treatment response tools

Webcasts
View
Metabolism, Alcohol & Toxicity
Why we need to talk about NASH

Why we need to talk about NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Looking ahead: how to identify high-risk patients

Looking ahead: how to identify high-risk patients

Webcasts
View
Metabolism, Alcohol & Toxicity
Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Webcasts
View
Metabolism, Alcohol & Toxicity
The NASH treatment pipeline: focus on anti-metabolic approaches

The NASH treatment pipeline: focus on anti-metabolic approaches

Webcasts
View
Metabolism, Alcohol & Toxicity
Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

Webcasts
View
Displaying 73 - 84 of 120